1. Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23(9):1147–1157. https://doi.org/10.1038/nbt1137
2. ADC REVIEW. (2017) Gemtuzumab Ozogamicin (Mylotarg) Drug Description. https://www.adcreview.com/gemtuzumab-ozogamicin-mylotarg/ Accessed 22 November 2017
3. Administration, U.S.F.D. (2017a) FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML. Available online : https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gemtuzumab-ozogamicin-cd33-positive-aml. Accessed 1 Sep 2017a
4. Administration, U.S.F.D. (2017b) FDA Approved Mylotarg for Treatment of Acute Myeloid Leukemia. https://www.fda.gov/news-events/press-announcements/fda-approves-mylotarg-treatment-acute-myeloid-leukemia Accessed 01 September 2017b
5. Administration, U.S.F.D. (2019) FDA approves polatuzumab vedotin-piiq for diffuse large B-cell lymphoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-polatuzumab-vedotin-piiq-diffuse-large-b-cell-lymphoma Accessed 10 June 2019